| Cutaneous lymphoproliferative disorders research | Lifetime | 1 | CH 1 | 99.96 |
| CAR-T cell therapy research | Lifetime | 11 | CH 1 | 99.95 |
| Cutaneous Melanoma Detection and Management | Lifetime | 5 | CH 1 | 99.93 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 31 | CH 1 | 99.90 |
| Melanoma and MAPK Pathways | Lifetime | 7 | CH 1 | 99.92 |
| Nonmelanoma Skin Cancer Studies | Lifetime | 8 | CH 1 | 99.74 |
| T-cell and Retrovirus Studies | Lifetime | 11 | CH 1 | 99.63 |
| Immunotherapy and Immune Responses | Lifetime | 60 | CH 4 | 99.88 |
| Cancer and Skin Lesions | Lifetime | 22 | CH 2 | 99.55 |
| Lymphoma Diagnosis and Treatment | Lifetime | 65 | CH 2 | 99.75 |
| Hedgehog Signaling Pathway Studies | Lifetime | 31 | CH 1 | 99.25 |
| HER2/EGFR in Cancer Research | Lifetime | 212 | CH 4 | 99.04 |
| Colorectal Cancer Treatments and Studies | Lifetime | 300 | CH 4 | 99.04 |
| Computational Drug Discovery Methods | Lifetime | 542 | CH 15 | 97.69 |
| Virus-based gene therapy research | Lifetime | 765 | CH 15 | 97.93 |
| Synthesis of Tetrazole Derivatives | Lifetime | 38 | CH 1 | 96.70 |
| Nail Diseases and Treatments | Lifetime | 241 | CH 6 | 97.81 |
| Autoimmune Bullous Skin Diseases | Lifetime | 278 | CH 6 | 97.92 |
| vaccines and immunoinformatics approaches | Lifetime | 194 | CH 10 | 97.66 |
| Fungal Infections and Studies | Lifetime | 310 | CH 5 | 97.87 |
| Cell Adhesion Molecules Research | Lifetime | 826 | CH 19 | 97.64 |
| Brain Metastases and Treatment | Lifetime | 384 | CH 11 | 97.43 |
| Ocular Oncology and Treatments | Lifetime | 190 | CH 3 | 96.62 |
| Skin Protection and Aging | Lifetime | 274 | CH 2 | 97.46 |
| Protein Degradation and Inhibitors | Lifetime | 545 | CH 7 | 96.14 |
| melanin and skin pigmentation | Lifetime | 377 | CH 5 | 96.22 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 318 | CH 11 | 96.27 |
| Histone Deacetylase Inhibitors Research | Lifetime | 612 | CH 6 | 94.82 |
| Dermatologic Treatments and Research | Lifetime | 503 | CH 9 | 95.37 |
| Genetic and rare skin diseases. | Lifetime | 224 | CH 7 | 95.14 |
| Infectious Diseases and Mycology | Lifetime | 462 | CH 4 | 94.60 |
| Tumors and Oncological Cases | Lifetime | 662 | CH 9 | 94.42 |
| Vascular Tumors and Angiosarcomas | Lifetime | 442 | CH 11 | 94.82 |
| Laser Applications in Dentistry and Medicine | Lifetime | 940 | CH 18 | 91.25 |
| Chemotherapy-related skin toxicity | Lifetime | 521 | CH 8 | 86.58 |
| Tattoo and Body Piercing Complications | Lifetime | 491 | CH 5 | 57.26 |
| Immunotherapy and Immune Responses | 2021-2025 | 9 | CH 1 | 99.70 |
| CAR-T cell therapy research | 2021-2025 | 13 | CH 1 | 99.83 |
| Melanoma and MAPK Pathways | 2021-2025 | 4 | CH 1 | 99.83 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 75 | CH 2 | 99.70 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 8 | CH 1 | 98.63 |
| Cutaneous Melanoma Detection and Management | 2021-2025 | 16 | CH 1 | 99.48 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 4 | CH 1 | 98.09 |
| Cancer and Skin Lesions | 2021-2025 | 11 | CH 1 | 97.73 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 28 | CH 1 | 97.92 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 114 | CH 2 | 98.43 |
| Ocular Oncology and Treatments | 2021-2025 | 72 | CH 2 | 93.90 |
| Virus-based gene therapy research | 2021-2025 | 337 | CH 6 | 92.23 |
| Brain Metastases and Treatment | 2021-2025 | 364 | CH 12 | 91.20 |
| Genetic and rare skin diseases. | 2021-2025 | 203 | CH 3 | 69.57 |
| GDF15 and Related Biomarkers | 2021-2025 | 707 | CH 9 | 50.40 |
| Synthesis of Tetrazole Derivatives | 2021-2025 | 221 | CH 1 | 51.21 |
